Clinical Trial Update: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 genotyping-based trial evaluating talazoparib in patients with somatic BRCA-mutant metastatic breast cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Talzenna (talazoparib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING